INGAP Peptide - Exsulin Corporation
Alternative Names: Exsulin; INGAP-PeptideLatest Information Update: 17 Jan 2018
At a glance
- Originator Eastern Virginia Medical School; McGill University
- Developer Exsulin Corporation; Jewish General Hospital
- Class Cytokines; Peptide fragments
- Mechanism of Action Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 17 Jan 2018 Discontinued - Phase-II for Type-1 diabetes mellitus (Combination therapy) in Canada (SC)
- 17 Jan 2018 Discontinued - Phase-II for Type-1 diabetes mellitus (Monotherapy) in Canada and USA (SC)
- 17 Jan 2018 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)